Livtencity
Livtencity ingredients
| Active ingredient | Strength |
|---|---|
| Maribavir | 200 mg/1 |
What Livtencity is used for
The FDA lists the approved uses on the official label (below). In the EU, maribavir is approved as Livtencity for:
LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). Consideration should be given to official guidance on the appropriate use of antiviral agents.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Livtencity
- Generic name
- Maribavir
- Made by
- Takeda Pharmaceuticals America, Inc.
- Forms
- Tablet, Coated
- Given
- Oral
- Drug class
- Cytomegalovirus pUL97 Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA215596
- On the US market since
- 2021
Official information
- Livtencity prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Maribavir)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Livtencity?
Livtencity (Maribavir) is a cancer medicine made by Takeda Pharmaceuticals America, Inc., approved by the US FDA.
What are the ingredients of Livtencity?
Livtencity contains Maribavir (200 mg/1).
Is Livtencity approved in Europe?
The same active substance is approved in the EU as Livtencity.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA